Pure Global AI
NCT06049030Not yet recruiting

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

A Phase Ia/Ib Study of HS-10516 to Investigate the Safety, Tolerance, Pharmacokinetic and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
HS-10516
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Timeline & enrollment
Phase
Phase 1
Start date
Sep 25, 2023
End date
Sep 25, 2025
Enrollment
190 participants
Primary outcome

Phase Ia: MTD/MAD of HS-10516,Phase Ib: Objective Response Rate (ORR) by Independent Review Committee (IRC)

Summary

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum
 acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary
 efficacy of HS-10516 in ccRCC.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06049030
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06049030 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 190 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.